Abstract: The present disclosure provides methods of preparing perivascular tissue lysates and methods of preparing mesenchymal stem cell (e.g., perivascular stem cell) lysates and total protein products from cultured cells (e.g., cultured perivascular stromal cells). The disclosure also features compositions containing such lysates and total protein products and methods of using the lysates in skincare applications, dermatological applications, cell culture applications, and to treat autoimmune or inflammatory diseases or conditions, local inflammation, and angiogenesis-related diseases or conditions.

Abstract: Compositions, products and devices are provided for promoting wound healing. The compositions, products and devices have a topographical complex surface.

Abstract: The invention features compositions including genetically modified human umbilical cord perivascular cells (HUCPVCs), medium conditioned by HUCPVCs (e.g., genetically modified HUCPVCs), the soluble fraction of medium conditioned by HUCPVCs (e.g., genetically modified HUCPVCs), and pharmaceutical compositions thereof, and methods of use thereof for treatment of wounds.

Abstract: Herein described is a method for treating cancer in a subject by administering a human umbilical cord perivascular cell (HUCPVC) that has been genetically modified to increase the expression of an oligonucleotide or a polypeptide such as an anti-cancer antibody.

Abstract: Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbours osteogenic progenitor cells and MHC?/? progenitor cells, and is useful to grow and repair human tissues including bone.

Abstract: Described is a method of expanding human progenitor cells by suspension culturing under non-static conditions. The culturing method provides a three-dimensional space for the rapid expansion of desirable progenitors. By this method, a new compartment of multipotential progenitor cells has been identified, which give rise under differentiation conditions to progeny including osteoblasts, chondrocytes, myoblasts, adipocytes, and other non-hematopoietic cell types. Their use in cell and tissue-based engineering is described.

Abstract: Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbors osteogenic progenitor cells and MHC?/? progenitor cells, and is useful to grow and repair human tissues including bone.

Abstract: Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbors osteogenic progenitor cells and MHC?/? progenitor cells, and is useful to grow and repair human tissues including bone.

Abstract: Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbours osteogenic progenitor cells and MHC?/? progenitor cells, and is useful to grow and repair human tissues including bone.

Abstract: Described herein is a method for modulating an immune reaction between lymphocytes and a body recognized by the lymphocytes as foreign. The method exploits the immunomodulating activity of a new class of progenitor cells termed HUCPVCs derived from the perivascular region of human umbilical cord. The method can also employ soluble factors exuded by cultured HUCPVCs. The method is useful to treat immune disorders including graft versus host disease, autoimmune disorders, and the like.

Abstract: Described herein is a method for modulating an immune reaction between lymphocytes and a body recognized by the lymphocytes as foreign. The method exploits the immunomodulating activity of a new class of progenitor cells termed HUCPVCs derived from the perivascular region of human umbilical cord. The method can also emply soluble factors exuded by cultured HUCPVCs. The method is useful to treat immune disorders including graft versus host disease, autoimmune disorders, and the like.

Abstract: Viable progenitor cells are extracted from frozen umbilical cord tissue. In embodiments, the umbilical cord tissue is a blood vessel bearing perivascular Wharton's jelly, and the extracted progenitor cells are HUCPVCs.

Abstract: Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbours osteogenic progenitor cells and MHC?/? progenitor cells, and is useful to grow and repair human tissues including bone.

Abstract: Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbors osteogenic progenitor cells and MHC?/? progenitor cells, and is useful to grow and repair human tissues including bone.

Abstract: Described herein is a method for modulating an immune reaction between lymphocytes and a body recognized by the lymphocytes as foreign. The method exploits the immunomodulating activity of a new class of progenitor cells termed HUCPVCs derived from the perivascular region of human umbilical cord. The method can also emply soluble factors exuded by cultured HUCPVCs. The method is useful to treat immune disorders including graft versus host disease, autoimmune disorders, and the like.

Abstract: Viable progenitor cells are extracted from frozen umbilical cord tissue. In embodiments, the umbilical cord tissue is a blood vessel bearing perivascular Wharton's jelly, and the extracted progenitor cells are HUCPVCs.

Abstract: The present invention relates to a method of coating a porous material such as a medical implant with a layer of calcium phosphate, wherein the material is submersed in an aqueous solution of calcium, phosphate and carbonate ions, and the pH of the solution is gradually increased. A calcium phosphate coating is formed on an internal surface of the porous material by agitating the solution during coating formation.

Abstract: Described herein is a method for modulating an immune reaction between lymphocytes and a body recognized by the lymphocytes as foreign. The method exploits the immunomodulating activity of a new class of progenitor cells termed HUCPVCs derived from the perivascular region of human umbilical cord. The method can also employ soluble factors exuded by cultured HUCPVCs. The method is useful to treat immune disorders including graft versus host disease, autoimmune disorders, and the like.

Abstract: Viable progenitor cells are extracted from frozen umbilical cord tissue. In embodiments, the umbilical cord tissue is a blood vessel bearing perivascular Wharton's jelly, and the extracted progenitor cells are HUCPVCs.

Abstract: The present invention relates to a method of coating a porous material such as a medical implant with a layer of calcium phosphate, wherein the material is submersed in an aqueous solution of calcium, phosphate and carbonate ions, and the pH of the solution is gradually increased. A calcium phosphate coating is formed on an internal surface of the porous material by agitating the solution during coating formation.